- Conditions
- Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
- Interventions
- Maraviroc, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 1:26 AM EDT